All News

kidney-147499_640.png

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis

Jack Cush, MD

A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.

Read Article
JAK Janus

New indications for JAK inhibitors

Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
SLE,malar,black

Damage in Childhood Lupus

EurekAlert!

Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.

Read Article
steroids.prednisone.pills_.jpg

Update on low-dose glucocorticoids in SLE

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Glucocorticoids (GC) have been the mainstay of treatment in SLE for nearly three quarters of a century. GC induce a range of anti-inflammatory effects, quickly relieve some symptoms and lower mortality in some life-threatening flares. However, they also have multiple side effects that limit the duration of treatment, as well as the dose used. Accordingly, the 2023 EULAR recommendations for SLE set a target dose of ≤5mg/day. Is low dose GC an achievable target?

Read Article
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/xXLiGFoU3L https://t.co/Sy36aOG81Y

Links:

Dr. John Cush RheumNow ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd

Links:

Dr. John Cush RheumNow ( View Tweet)
Cognitive Function in Older Adults: Worse in Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk

Links:

Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria. https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f

Links:

Dr. John Cush RheumNow ( View Tweet)
Damage in Childhood Lupus Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise. https://t.co/wCygK0LGvd https://t.co/tm8LTI28mh

Links:

Dr. John Cush RheumNow ( View Tweet)
We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria. https://t.co/mrr5MWxeJz https://t.co/0FMLaAxaWV

Links:

Dr. John Cush RheumNow ( View Tweet)
Update on low-dose glucocorticoids in SLE GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions. https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W

Links:

Dr. John Cush RheumNow ( View Tweet)
Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon? Pregnancy in lupus patients raises concerns due to potential complications like preeclampsia, eclampsia, and increased mortality rates for both mother and baby. https://t.co/Kv6F21UHze https://t.co/ya8lAkSLC2

Links:

Dr. John Cush RheumNow ( View Tweet)
Missed the Live #EULAR2024 #lupus #SLE Topic Recap session yesterday? You can catch up using the link below. https://t.co/NYJgNb5ME0 @RheumNow @andreafava https://t.co/eeoSux6Csl

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. https://t.co/y9QPieV0py https://t.co/GzwntEJLve

Links:

Dr. John Cush RheumNow ( View Tweet)
3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria, including abstracts POS0732 and OP0255. https://t.co/XD1EJW2nNE https://t.co/jALVfebb8t

Links:

Dr. John Cush RheumNow ( View Tweet)
Belimumab’s Sustained Impact in Lupus SLE a chronic autoimmune multi-system inflammatory condition, can present with various, sometimes severe, clinical manifestations, leading to high levels of morbidity including impact on quality of life. https://t.co/4Gf5SJN5FG https://t.co/LxCjLQkaYQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Summary of #EULAR2024 #ClinicalPearls JAKi have expanding disease data ✅ #GCA w #UPA ✅ Awaiting data in #SLE w #UPA & #Deucravacitinib ✅Use in #JIA ✅No new safety signals @rheumnow @eular_org

Janet Pope Janetbirdope ( View Tweet)

Does B Cell Depletion Matter? Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna, Austria. https://t.co/IjxGWWjoGD https://t.co/GwLjB4Z7ub

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×